152 results on '"Tehfe M"'
Search Results
2. 1309P CD8+ T cell infiltration is associated with improved survival in advanced pancreatic cancer
3. CN12 Impact of diet on immune checkpoint blockade: Nurse-directed dietary intervention
4. EP07.03-002 Combined Classifications for Thymoma and Thymic Carcinoma From a 10 years CHUM University Hospital Real-world Experience
5. 1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)
6. Prospective Neurocognitive Functions of Patients Treated With Concurrent Nivolumab and Stereotactic Brain Radiosurgery for NSCLC and RCC Brain Metastases
7. 1213P Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in a real-life setting (CLEAR)
8. 390MO Colorectal (CRC) cancer screening and diagnosis during the COVID-19 pandemic in Quebec, Canada
9. LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
10. 1425P Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
11. 1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
12. Erratum: Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020
13. 493P Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D
14. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
15. LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
16. Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020
17. P1.04-01 Body Mass Index and Age Do Not Influence Survival in Patients with Lung Cancers Treated with PD1/PDL1 Immune Checkpoint Inhibitors
18. Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
19. Cancer patient participation and compliance in microbiome sample collection: An oncology research nurse’s experience
20. MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226
21. Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D
22. Impact of the Continuity of Nursing Care Delivered by a Pivot Nurse in Oncology on Improving Satisfaction and Quality of Life of Patients With Advanced Lung Cancer
23. P3.08-16 Prognostic Value of PDL-1 Expression and Correlation Between Primary Tissue and Brain Metastases in Oligometastatic NSCLC
24. Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer
25. MA08.11 Early Safety Data of a Phase I/II Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients with NSCLC
26. P1.13-19 Treatment Cessation for Improved Detection of EGFR-Mutated Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer (aNSCLC)
27. Eastern Canadian Colorectal Cancer Consensus Conference 2017
28. 231P_PR Impact of the continuity of nursing care delivered by a pivot nurse in oncology on improving satisfaction and quality of life of patients with advanced lung cancer
29. 514P Updated analysis of outcomes of elderly patients with resectable liver metastases from colorectal cancer (CRLM): Single center experience
30. MA 10.01 Durvalumab ± Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226
31. Factors Influencing Treatment Selection and Survival in Advanced Lung Cancer
32. A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts
33. A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226)
34. CN111 - Cancer patient participation and compliance in microbiome sample collection: An oncology research nurse’s experience
35. 608P - Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D
36. 474P - Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
37. Corrigendum: Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014
38. Eastern Canadian Colorectal Cancer Consensus Conference 2013: Emerging Therapies in the Treatment of Pancreatic, Rectal, and Colorectal Cancers
39. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014
40. 119P - A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts
41. 289 - A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226)
42. Eastern Canadian Colorectal Cancer Consensus Conference: Standards of Care for the Treatment of Patients with Rectal, Pancreatic, and Gastrointestinal Stromal Tumours and Pancreatic Neuroendocrine Tumours
43. Clinical Features and Course of Brain Metastases in Colorectal Cancer: An Experience from a Single Institution
44. A Phase 2 Randomized Open-Label Study of Ramucirumab (IMC 1121b; RAM) in Combination with Platinum-Based Chemotherapy in Patients (PTS) with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Results From Non-Squamous (NSQ) PTS (NCT01160744)
45. Eastern Canadian Colorectal Cancer Consensus Conference: Application of New Modalities of Staging and Treatment of Gastrointestinal Cancers
46. Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer
47. Characteristics and treatment effect of senior patients with metastatic colorectal cancer (mCRC): A retrospective analysis.
48. Eastern Canadian Colorectal Cancer Consensus Conference: Setting the Limits of Resectable Disease
49. Clinical features and course of brain metastases in colorectal cancer: Experience from a single institution.
50. Long Wavelength Cationic Photopolymerization in Aerated Media: A Remarkable Titanocene/Tris(trimethylsilyl)silane/Onium Salt Photoinitiating System.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.